Abbott Laboratories NYSE:ABT Price, Chart, News & Insight

Abbott Partners With Google to Bring AI-Powered Glucose Insights to Everyday Health

Abbott (NYSE: ABT) announced a multi-year partnership with Google Health aimed at combining continuous glucose monitoring with artificial intelligence to provide more personalized health insights.

Under the partnership, glucose data from Abbott’s Lingo biowearable will be integrated into the Google Health app alongside other health and wellness information. Google Health Coach will use the data to generate personalized recommendations related to nutrition, physical activity, sleep and recovery.

The companies also plan to conduct what they describe as one of the largest real-world metabolic health studies, combining continuous glucose, wearable, laboratory and survey data. Findings are expected to help improve future AI coaching and Lingo features.

For Abbott, the agreement could broaden the role of its continuous glucose monitoring technology beyond traditional diabetes management. Lingo is an over-the-counter CGM designed for adults who do not use insulin, allowing users to track how factors such as food, exercise, sleep and stress affect glucose levels.

The collaboration also strengthens Abbott’s exposure to the growing intersection of wearable health technology and AI. Lingo integrations within Google Health are expected to begin rolling out later in 2026.

💬

The Investor 08-11-26

Abbott Laboratories announced it has received U.S. FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 AI-powered coronary imaging platform.

The system combines optical coherence tomography (OCT) imaging with AI-driven insights to help physicians better assess arterial blockages and optimize stent placement during minimally invasive heart procedures. The platform enables real-time decision-making, improved accuracy, and faster workflows, aiming to enhance patient outcomes in complex coronary artery disease cases.

Abbott highlighted that the technology provides high-resolution imaging and automated analysis, supporting more precise and efficient treatment planning for procedures such as percutaneous coronary intervention (PCI).

Source: Abbott press release, PRNewswire

💬

The Investor 04-28-26

Abbott presented new clinical data highlighting strong outcomes for its technologies targeting heart rhythm disorders at the Heart Rhythm Society 2026 conference. The results covered multiple trials across its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios, including treatments for atrial fibrillation.

Six-month data from the FlexPulse study showed high success rates, with 87% of patients free from arrhythmias and a strong safety profile, while additional studies demonstrated promising results for Abbott’s investigational pacing and defibrillation devices.

The company said the findings reinforce the effectiveness and safety of its technologies and support ongoing innovation in treating complex cardiac conditions through more advanced and personalized therapies.
PRNewswire

💬

The Investor 04-26-26

Abbott announced new clinical data demonstrating progress in its Cancerguard multi-cancer early detection (MCED) test at the 2026 American Association for Cancer Research (AACR) Annual Meeting, highlighting improved early-stage cancer detection using a multi-biomarker approach.

The data show that combining methylation and protein biomarkers enhances detection across cancer types and stages, with each biomarker contributing independently. In a case-control study, nearly half of detected cancer signals came from methylation alone, while additional cases were identified through protein-only and combined biomarker signals, supporting broader and earlier detection.

Separately, long-term results from the DETECT-A study—recognized with an AACR award—demonstrated the potential clinical impact of blood-based MCED testing. The study identified multiple cancer types, including those without routine screening, and reported that patients diagnosed at early stages remained alive and cancer-free after several years of follow-up.

Abbott emphasized that multi-cancer early detection could play a significant role in improving screening, particularly as a large proportion of cancers currently lack standard screening methods. The Cancerguard test, which uses a simple blood draw, is designed to detect multiple cancers at early stages, though it has not yet received regulatory approval.
PRNewswire

💬

European Investor 04-18-26

Abbott Laboratories reported first-quarter 2026 results in line with expectations, posting GAAP diluted earnings per share of $0.61 and adjusted EPS of $1.15, up 6% year-over-year, while total sales rose 7.8% on a reported basis.

A key highlight of the quarter was the completion of Abbott’s acquisition of Exact Sciences, positioning the company as a major player in the rapidly growing oncology diagnostics market and adding a new high-growth segment to its portfolio.

Abbott maintained a positive outlook for 2026, projecting full-year comparable sales growth of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58, including a modest dilution impact from the acquisition. The company also reported progress across its medical technology pipeline, including advancements in cardiovascular devices and diabetes management solutions, supporting expectations for accelerating growth through the year.
PRNewswire

💬

Global Finance News 04-17-26

Abbott announced a partnership with Flatiron Health to integrate its Precision Oncology portfolio into the OncoEMR® platform.

The integration enables oncologists to order diagnostic tests and access results directly within their existing clinical workflow, improving efficiency and reducing administrative burden.

The move expands access to Abbott’s oncology tests across Flatiron’s network of more than 1,600 cancer care centers and 4,700 providers in North America.

The companies said the collaboration will support faster, data-driven treatment decisions and enhance personalized cancer care by embedding diagnostics into everyday clinical practice.
PRNewswire

💬

WS Investor 03-30-26

Abbott announced it has completed the acquisition of Exact Sciences, strengthening its position in cancer screening and diagnostics.

The deal expands Abbott’s portfolio with leading products such as Cologuard and Oncotype DX, while adding a pipeline focused on early cancer detection and personalized treatment.

The acquisition positions Abbott to compete in a fast-growing $60 billion market, supporting its strategy to advance preventative and precision healthcare solutions.
PRNewswire

💬

WS Investor 03-23-26

Abbott Laboratories announced results from the FreeDM2 randomized controlled trial showing that its FreeStyle Libre technology helped people with Type 2 diabetes using basal insulin improve glucose management compared with traditional fingerstick monitoring.

The U.K.-based study involved 303 participants across 24 clinical sites and compared continuous glucose monitoring with standard self-monitoring of blood glucose. After four months, participants using the Libre system experienced a 0.6 percentage-point greater reduction in HbA1c levels and spent about 2.5 additional hours per day within the healthy glucose range of 70–180 mg/dL.

Researchers said the improvements were driven by patient self-management, as users relied on real-time glucose data from the device to adjust daily decisions related to diet, insulin dosing and physical activity. Participants in the trial were already receiving advanced therapies, including SGLT2 inhibitors or GLP-1 receptor agonists.

A separate clinical study conducted in Italy involving 88 adults with Type 2 diabetes reported similar improvements after three months of using the Libre system, including better average glucose levels, increased time in the healthy range and improved quality of life.

Abbott said the results support broader access and reimbursement for continuous glucose monitoring among patients using basal insulin, a group that often lacks coverage in many healthcare systems despite the potential for improved glucose control. The company’s Libre platform is currently used by roughly eight million people in more than 60 countries.
PRNewswire

💬

European Investor 03-12-26

Abbott reported new research showing that cases of diabetic ketoacidosis (DKA) are increasing globally while ketone monitoring among people with diabetes remains inconsistent.

A long-term analysis of nearly 660,000 individuals in the United Kingdom found that DKA incidence more than tripled among people with Type 1 diabetes and increased sixfold among those with Type 2 diabetes, with many patients experiencing repeat episodes. Additional studies from France and the United States showed that many patients do not regularly test ketone levels despite awareness of the risks, and clinicians lack standardized guidance on ketone monitoring practices.

Abbott said the findings highlight the need for improved tools and clearer clinical guidance to detect rising ketones earlier and help prevent DKA, a potentially life-threatening complication of diabetes.

💬

The Investor 03-11-26

Abbott declares quarterly dividend; extends 54-year growth streak

Abbott’s board of directors declared a quarterly common dividend of $0.63 per share. The dividend will be paid on May 15, 2026, to shareholders of record as of April 15, 2026.

This payment marks Abbott’s 409th consecutive quarterly dividend since 1924.

💬

Global Finance News 02-21-26

NYSE:ABTFollow

NYSE:ABT